Edition:
United Kingdom

People: Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

0.61USD
22 Aug 2019
Change (% chg)

$-0.03 (-4.90%)
Prev Close
$0.64
Open
$0.64
Day's High
$0.65
Day's Low
$0.61
Volume
33,106
Avg. Vol
33,285
52-wk High
$1.32
52-wk Low
$0.55

Heyrman, Reinilde 

Dr. Reinilde Heyrman, M.D., is Vice President, Chief Clinical Development Officer and Secretary of Bellerophon Therapeutics LLC, since February 2014. Prior to joining us, Dr. Heyrman served as Vice President, Chief Clinical Development Officer of Ikaria from March 2012 to February 2014. Dr. Heyrman held several positions at Daiichi Sankyo Pharma Development, a pharmaceutical company, from 2005 to March 2012, most recently as Vice President, Clinical Development from 2009 to March 2012. From 2001 to 2002 and 2002 to 2005, Dr. Heyrman served as Director Clinical Research and Senior Director Clinical Research, respectively, at Sankyo Pharma Development, a pharmaceutical company. Dr. Heyrman received an M.D. from the University of Antwerp, Belgium.

Basic Compensation

Total Annual Compensation, USD 655,528
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 79,246
Fiscal Year Total, USD 734,774

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --